| ELISA and Western blot analysis
Recombinant MERS-N was produced in BL21 cells as described previously.
2 MERS-N ELISAs were also performed as previously described. 2 For Western blot analysis, 1 μg purified N, pET control lysate, or 0.5 μg purified S was run on an SDS page and transferred to a PVDF membrane. Sera, without MER-CoV reactivity (NHS) and against SARS, 229E, OC43, HKU1, and MERS-CoV, diluted at 1:400 were used to probe the blots with HRP goat anti human IgA, IgG, IgM (H and L). The blot was developed with DAB.
| ROC analysis
Receiver-operating characteristic (ROC) analysis was used to determine diagnostic sensitivity, specificity, and optimal test cut-off OD ( Figure 1A ). Using an OD cutoff of 0.2, one of the 400 normal human sera (0.25%) was above cutoff.
In order to precisely test the specificity and sensitivity of the S ELISA, nine true negative sera with reciprocal endpoint microneutralization titers less than 20 and nine true positive sera with reciprocal endpoint microneutralization titers ranging from 20 to 640, were tested at dilutions of 200, 400, 800, and 1600 ( Figure 1B ). ROC analysis was performed to calculate the diagnostic sensitivity (true positive) and specificity (true negative) of the assay. At a standard screening dilution of 1:400, the sensitivity of the S ELISA remained at 89% or greater at ODs <0.51 ( Figure 1C ). Specificity increased to 89%
at an OD of 0.09 and 100% at 0.39 ( Figure 1C ). At serum dilutions of 1:800 and 1:1600, the S ELISA remains highly specific, but loses sensitivity at higher ODs as can be expected ( Figures 1D and 1E ). and N, at lower ODs, the S ELISA is more specific, while the N ELISA retains higher sensitivity across a large range of ODs. These data are not consistent with one publication examining serial blood draws from a single MERS-CoV patient has suggested their S ELISA is more sensitive than an N ELISA. 15 We have observed significant patient-to-patient differences in the quality and quantity of polyclonal antibody responses, and these conflicting data may be simply explained by human variation in immune response.
Recent work examining a panel of MERS-CoV patient serum has suggested that S ELISA sensitivity can be increased by lowering the breakpoint in MERS-CoV S ELISAs. 16 While doing this would capture a larger percentage of patients who seroconvert, we have seen several patients who never develop detectable MERS-CoV S antibodies, but do develop N antibodies (data not shown).
A second reason to retain both N and S ELISAS is there is evidence that antibodies against other coronavirus N proteins are detected earlier during infection than S proteins. Specifically, SARS-CoV infection studies have indicated that antibodies against the N protein appear before antibodies against the S protein. 17, 18 We frequently receive serum from patients who are acutely ill with suspected MERS- Third, while N ELISA may be more sensitive, examination of N and S cross reactivities suggest that antibodies directed against N, but not S, may cross react with within-group coronaviruses, 19 therefore using both N and S ELISAS may capture both sensitivity and specificity information.
As part of our screening process, we aim to capture as many potential positive serum as possible, and then perform confirmatory assays. In summary, during our new testing algorithm, both N and S ELISAS will be used as screening assays with sera diluted to 1:400. For all sera with ODs above assay cutoff, they will be diluted serially, fourfold from 1:100-1:6400 and used for endpoint titer determinations. Sera that are positive for either N or S or both N and S (titers at 1:400, 1:1600, or 1:6400), will be tested via microneutralization with live MERS-CoV along with 10% of negative sera. We will define positive MERS-CoV serology as positive in two of three assays tested, N ELISA, S ELISA, and microneutralization or positive by microneutralization alone with microneutralization activity as confirmed positive.
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